A parliamentary committee today sought creation of a separate drug controller for AYUSH medicines and drugs in a time-bound manner to ensure they are on a par with international standards.
The committee, which pointed out that market of Indian herbal drugs was declining worldwide, lamented the delay by the AYUSH ministry in fulfilling the assurance given on the issues of separate drug controller and legislations for education and practice of AYUSH systems of medicine.
According to the report submitted in the Lok Sabha today, the ministry had moved a proposal for setting up a separate drug controller for AYUSH medicines and it was put up for Cabinet approval.
However, upon a directive from PMO, the ministry decided to set up a vertical structure of AYUSH in the existing Central Drugs Standard Control Organization (CDSCO).
"Putting AYUSH drugs under the same structure of CDSCO as allopathic medicines is gross injustice towards AYUSH medicines and will not lead to fulfilment of the assurance which was give," the report stated.
Since an inordinate length of time has been taken by the ministry without fulfilling the assurance, the committee directed the ministry to fulfil it in a time-bound manner and, meanwhile, also furnish a part implementation report detailing steps taken by it to ensure quality, safety, efficacy and standard of AYUSH drugs in the country.
The committee pointed out that two more assurances pertaining to the legislation for education and practice of AYUSH systems of medicine have been kept pending by the ministry for more than two years.
The committee expressed concern to note that there is no licensing authority for AYUSH medicines despite the fact that these are eternal medicinal practices.
It observed that absence of licensing authority for AYUSH medicines is the main reason for these medicines not getting the recognition they deserve in the country and abroad.
It also pointed out that there are no specific pharmacists for selling AYUSH medicines and no course has been prescribed for them as a result of which many countries have banned AYUSH medicines in their markets.
The committee also asked the Ministry of AYSUH to streamline the mechanism for implementation of eight assurances given by the government which are still pending.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
